MedTrace Logo

Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies

NCT06550102 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2024-08-15

No results posted yet for this study

Summary

This study is a prospective, non-randomized feasibility study of drug response profiling (DRP) in pediatric blood cancers. Primary cancer cells are isolated from patients and screened ex vivo at single-cell resolution using automated fluorescence microscopy. Drug sensitivity fingerprints are integrated with genetic annotations to inform the treating physician about personalized treatment options. The study aims to determine the practicability of real-time drug response profiling and its actionability in identifying patient-specific cancer dependencies in refractory disease settings.

Conditions

Sponsors & Collaborators

  • University Children's Hospital, Zurich

    lead OTHER

Principal Investigators

  • Jean-Pierre Bourquin, MD, PhD · University Children's Hospital Zurich

Eligibility

Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-04
Primary Completion
2031-12-31
Completion
2031-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06550102 on ClinicalTrials.gov